PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.12%
Cash & equivalents declining -1.12% while CRVO's grows 0.00%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Both CRVO and the company show zero Cash + Short-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of CRVO's -97.96%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of CRVO's -19.52%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.86%
Less than half of CRVO's -38.67%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.96%
Less than half of CRVO's -31.98%. David Dodd sees a more disciplined short-term liability approach.
4.78%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
10.65%
Less than half of CRVO's -28.19%. David Dodd sees far fewer liability expansions relative to competitor.
382.94%
Above 1.5x CRVO's 1.49%. Michael Burry suspects heavy new equity expansion or dilution.
-3.62%
Below half CRVO's -10.28%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-10.94%
Below half CRVO's 1010.38%. Michael Burry sees potential underperformance in building shareholder capital.
-1.12%
Below half CRVO's -19.52%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Less than half of CRVO's -65.56%. David Dodd sees less overall debt expansion vs. competitor.
4.98%
Less than half of CRVO's -65.56%. David Dodd sees better deleveraging or stronger cash buildup than competitor.